Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-28T20:48:27.801Z Has data issue: false hasContentIssue false
  • English
  • Français

Clinical and experimental aspects of interactions between amine oxidase inhibitors and amine re-uptake inhibitors

Published online by Cambridge University Press:  09 July 2009

E. Marley  and
Krystyna M. Wozniak
E. Marley*
Affiliation:
Department of Pharmacology, Institute of Psychiatry, London
Krystyna M. Wozniak
Affiliation:
Department of Pharmacology, Institute of Psychiatry, London
*
1 Address for correspondence: Professor E. Marley, Department of Pharmacology, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF.
Get access Rights & Permissions [Opens in a new window]

Synopsis

Dangerous and even fatal interactions can occur in man following combinations of antidepressants which include non-selective MAO inhibitors. To ascertain the causation, interactions reproducing the clinical phenomena have been elicited in animals with these combinations, and the mechanisms involved have been explored by various pharmacological strategies; 5-HT re-uptake inhibitors proved especially hazardous in combination. Interactions could, however, be avoided even with the 5-HT re-uptake inhibitors, by combination with relatively selective MAO A or B inhibitors, an approach with potential clinical value.

Type
Research Article
Information
Psychological Medicine , Volume 13 , Issue 4 , November 1983 , pp. 735 - 749
Copyright
Copyright © Cambridge University Press 1983

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ahtee, L., Jounela, A. J., Saarnidaara, L. & Simola, I. (1974). Interactions of some analgesics and antidepressants with phenelzine or reserpine in the mouse. Pharmacology 12, 39–47.CrossRefGoogle ScholarPubMed
Ayd, F. J. Jr (1975). Psychotropic drug combinations: good and bad. In Drugs in Combination with Other Therapies (ed. Greenblatt, M.), pp. 165–188. Grune & Stratton: New York.Google Scholar
Beaumont, G. (1973). Drug interactions with clomipramine (Anafranil). Journal of International Medical Research 1, 480–484.CrossRefGoogle Scholar
Bedard, R. & Pycock, C. (1977). The ‘wet dog shake’ behaviour in the rat and 5-hydroxytryptamine. British Journal of Pharmacology 59, 150P.Google ScholarPubMed
Blackwell, B. & Marley, E. (1966 a). Interactions of cheese and its constituents with monoamine oxidase inhibitors. British Journal of Pharmacology 26, 120–141.Google ScholarPubMed
Blackwell, B. & Marley, E. (1966 b). Interactions of yeast extracts and their constituents with monoamine oxidase inhibitors. British Journal of Pharmacology 26, 142–161.Google ScholarPubMed
Bradley, P. B. & Marley, E. (1965). Effects of tryptamine and tryptamine homologues on cerebral electrical activity and behaviour in the cat. British Journal of Pharmacology 24, 659–674.Google ScholarPubMed
Buus-Lassen, J. & Squires, R. F. (1976). Potentiation of nialamideinduced hypermotility in mice by lithium and the 5-HT uptake inhibitors chiorimipramine and FG 4963. Neuropharmacology 15, 665–668.CrossRefGoogle Scholar
Clineschmidt, B. V. (1972). Spinal monoamines and the toxic interaction between monoamine oxidase inhibitors and tricyclic antidepressants. European Journal of Pharmacology 19, 126–129.CrossRefGoogle ScholarPubMed
Corne, S. J., Pickering, R. W. & Warner, B. T. (1963). A method for assessing the effects of drugs on the central actions of 5-hydroxytryptamine. British Journal of Pharmacology 20, 106–120.Google ScholarPubMed
Cox, B. & Lee, T. F. (1980). Comparison of core temperature changes induced by intrahypothalamic injection of 5-hydroxytryptamine and tryptamine in the rat. British Journal of Pharmacology 70, 149P.Google Scholar
Curzon, G., Fernando, J. C. R. & Lees, A. J. (1979). Backward walking and circling: behavioural responses induced by drug treatments which cause simultaneous release of catecholamines and 5-hydroxytryptamine. British Journal of Pharmacology 66, 573–579.CrossRefGoogle ScholarPubMed
Davidson, J., McLeod, M., Law-Yone, B. & Linnoila, M. (1978). A comparison of electroconvulsive therapy and combined phenelzine– amitnptyline in refractory depression. Archives of General Psychiatry 35, 639–642.CrossRefGoogle ScholarPubMed
Davies, E. B. (1963). Combining the antidepressants. Lancet ii, 781–782.CrossRefGoogle Scholar
Deakin, J. F. W. & Dashwood, M. R. (1981). The differential neurochemical bases of the behaviours elicited by serotonergic agents and by the combination of a monoamine oxidase inhibitor and L-DOPA. Neuropharmacology 20, 123–130.CrossRefGoogle ScholarPubMed
De Montigny, C., Grunberg, F., Maher, A. & De Schenes, J. P. (1981). Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. British Journal of Psychiatry 138, 252–256.CrossRefGoogle ScholarPubMed
Dixit, K. S., Dhasmana, K. M., Sinha, J. N. & Bhargava, K. P. (1970). Role of catecholamines in fatal hyperpyrexia induced by imipramine in MAOI treated rabbits. Archives Internationales de Pharmacodynamie et de Thérapie 188, 86–91.Google ScholarPubMed
Feldberg, W. (1975). Body temperature and fever: changes in our views during the last decade. The Ferrier Lecture 1974. Proceedings of the Royal Society B 191, 199–229.Google ScholarPubMed
Feldberg, W. & Lotti, V. J. (1967). Temperature response to monoamines and an inhibitor of MAO injected into the cerebral ventricles of rats. British Journal of Pharmacology and Chemotherapy 31, 152–161.CrossRefGoogle Scholar
Fuxe, K. & Ungerstedt, U. (1968). Histochemical studies on the effects of (+)-amphetamine, drugs of the imipramine group and tryptamine on central catecholamine and 5-hydroxytryptamine neurones after intraventricular injection of catecholamines and 5-hydroxytryptamine. European Journal of Pharmacology 4, 135–144.CrossRefGoogle ScholarPubMed
Gander, D. R. (1965). Treatment of depressive illnesses with combined antidepretsants. Lancet ii, 107–109.CrossRefGoogle Scholar
Garcha, G., Imrie, P. R., Marley, E. & Thomas, D. V. (1979). Effects of monoamine oxidase inhibitor (MAOI) pretreatment on the fate of intraduodenally instilled [14C]-tyramine. British Journal of Pharmacology 67, 454–455P.Google ScholarPubMed
Garcha, G., Imrie, P. R., Marley, E. & Thomas, D. V. (1983). Distribution and effects of intestinally administered [14]-tyramine in cats, modified by monoamine oxidase inhibitors. Journal of Psychiatric Research 17, 75–92.CrossRefGoogle Scholar
Goldberg, R. C. & Thornton, W. E. (1978). Combined tricyclic MAOI therapy for refractory depression: a review, with guidelines for appropriate usage. Journal of Clinical Pharmacology 18, 143–147.CrossRefGoogle ScholarPubMed
Gong, S. N. C. & Rogers, K. J. (1973). Role of brain monoamines in the fatal hyperthermia induced by pethidine or imipramine in rabbits pretreated with monoamine oxidase inhibitors. British Journal of Pharmacology 48, 12–18.CrossRefGoogle ScholarPubMed
Grahame-Smith, D. G. (1971). Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan. Journal of Neurochemistry 18, 1053–1066.CrossRefGoogle ScholarPubMed
Green, A. R. & Grahame-Smith, D. G. (1974). The role of brain dopamine in the hyperactivity syndrome produced by increased 5-hydroxytryptamine synthesis in rats. Neuropharmacology 13, 949–959.CrossRefGoogle ScholarPubMed
Green, A. R. & Youdim, M. B. H. (1975). Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration. British Journal of Pharmacology 55, 415–422.CrossRefGoogle ScholarPubMed
Greenblatt, D. J. & Shader, R. I. (1975). Drug interactions in psychopharmacology. In Manual of Psychiatric Therapies (ed. Shader, R. I.), pp. 269–279. Little, Brown: Boston.Google Scholar
Growdon, J. H. (1977). Postural changes, tremor and myoclonus in the rat immediately following injections of p-chloramphetamine. Neurology 27, 1074–1077.CrossRefGoogle Scholar
Hess, S. M. & Doepfner, W. (1961). Behavioural effects and brain amine content in rats. Archives Internationales de Pharmacodynamie 134, 89–99.Google ScholarPubMed
Himwich, W. A. (1962). Interaction of monoamine oxidase inhibitors with imipramine and similar drugs. In Recent Advances in Biological Psychiatry, Vol. 4 (ed. Wortis, J.), pp. 257–265. Plenum Press: New York.CrossRefGoogle Scholar
Himwich, W. A., Costa, E. & Himwich, H. E. (1961). Brain serotonin in relation to imipramine interaction with a monoamine oxidase inhibitor. In Neuropharmacology, Vol. 2 (ed. Rothlin, E.), pp. 485–489. Elsevier: Amsterdam.Google Scholar
Holman, R. B., Seagraves, E., Elliott, G. R. & Barchas, J. D. (1976). Stereotyped hyperactivity in rats treated with tranylcypromine and specific inhibitors of 5-HT re-uptake. Behavioural Biology 16, 507–514.CrossRefGoogle Scholar
Horn, A. S. & Snodgrass, S. R. (1973). The occurrence of tryptamine in rat brain and its pharmacological manipulation. British Journal of Pharmacology 47, 646P.Google ScholarPubMed
Jacobs, B. L. (1974). Evidence for the functional interaction of two central neurotransmitters. Psychopharmacologia 39, 81–86.CrossRefGoogle ScholarPubMed
Jacobs, B. L. (1976). An animal model for studying central serotonergic synapses. Life Sciences 19, 777–786.CrossRefGoogle ScholarPubMed
Jenner, P., Luscombe, G. & Marsden, C. D. (1980). 5-hydroxytryptamine (5HT) dependent myoclonus in the guinea-pig may provide evidence for multiple cerebral 5-HT receptors. British Journal of Pharmacology 70, 41–42P.Google Scholar
Jenner, P., Luscombe, G. & Marsden, C. D. (1981). Tryptamineinduced myoclonus in the guinea-pig suggests involvement of pre. and post-synaptic indoleamine mechanisms. British Journal of Pharmacology 74, 286P.Google Scholar
Johnston, J. P. (1968). Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochemical Pharmacology 17, 1285–1297.CrossRefGoogle ScholarPubMed
Jones, R. B. & Luscombe, D. K. (1976). Single dose studies with clomipramine in normal subjects. Postgraduate Medical Journal 52, (Suppl. 3), 62–67.Google ScholarPubMed
Jones, R. S. G. & Broadbent, J. (1982). Differential effects of fluoxetine and zimelidine on the uptake of 5-hydroxytryptamine and tryptamine by cortical slices and on responses of cortical neurones to stimulation of the nucleus raphe medianus. European Journal of Pharmacology 81, 681–685.CrossRefGoogle ScholarPubMed
Knoll, J. (1976). Analysis of the pharmacological effects of selective monoamine oxiclase inhibition. In Monoamine Oxidase and its Inhibition (eds. Wolstenholme, G. E. W. and Knight, J.), pp. 135–161. Elsevier: Amsterdam.Google Scholar
Knoll, J. & Magyar, K. (1972). Some puzzling effects of monoamine oxidase inhibitors. Advances in Biochemistry and Psychopharmacology 5, 393–408.Google ScholarPubMed
Laidlaw, P. P. (1912). The physiological action of indolethylamine. Biochemical Journal 6, 141–150.CrossRefGoogle ScholarPubMed
Leysen, J. E., Niemegeers, C. J. E., Tollenaere, J. P. & Laduron, P. M. (1978). Serotonergic component of neuroleptic receptors. Nature 272, 168–171.CrossRefGoogle ScholarPubMed
Ling, G. M., Nogai, M. & Hansen, S. (1961). Convulsive effects of tranylcypromine and imipramine in combination. Lancet ii, 1262.CrossRefGoogle Scholar
Loveless, A. H. & Maxwell, D. R. (1965). A comparison of the effects of imipramine, trimipramine, and some other drugs in rabbits treated with a monoamine oxidase inhibitor. British Journal of Pharmacology 25, 158–170.Google ScholarPubMed
Marley, E. & Blackwell, B. (1970). Interactions of monoamine oxidase inhibitors, amines and foodstuffs. Advances in Pharmacology and Chemotherapy 8, 185–239.CrossRefGoogle ScholarPubMed
Marley, E. & Vane, J. R. (1967). Tryptamines and spinal cord reflexes in cats. British Journal of Pharmacology and Chemotherapy 31, 447–465.CrossRefGoogle ScholarPubMed
Marley, E. & Wozniak, K. M. (1983 a). Interactions between non-selective amine oxidase inhibitors (MAOI) and other antidepressants. British Journal of Pharmacology 78, 20P.Google Scholar
Marley, E. & Wozniak, K. M. (1983 b). Interactions between relatively selective amine oxidase inhibitors (MAOI) and clomipramine. British Journal of Pharmacology 78, 21P.Google Scholar
Mendis, N., Pare, C. M. B., Sandler, M., Glover, V. & Stern, G. (1981). (−)-Deprenyl in the treatment of depression. In Monoamine Oxidase Inhibitors–the State of the Art (ed. Youdim, M. B. H. and Paykel, E. S.), pp. 171–176. Wiley: New York.Google Scholar
Mendlewicz, J. & Youdim, M. B. H. (1981). A selective MAO-B inhibitor (L-Deprenyl) and 5-HTP as antidepressant therapy. In Monoamine Oxidase Inhibitors–the State of the Art (ed. Youdim, M. B. H. and Paykel, E. S.), pp. 177–188. Wiley: New York.Google Scholar
Meyers, D. B., Kanyuck, D. O. & Anderson, R. C. (1966). Effect of chronic nortriptyline pretreatment on the acute toxicity of various medicinal agents in rats. British Journal of Pharmaceutical Sciences 55, 1317–1318.CrossRefGoogle ScholarPubMed
Nelson, J. C. & Byck, R. (1982). Rapid response to lithium in phenelzine non-responders. British Journal of Psychiatry 141, 85–86.CrossRefGoogle ScholarPubMed
Nymark, M. & Nielsen, I. M. (1963). Reactions due to the combination of monoamine oxidase inhibitors with thymoleptics, pethidine or methyl-amphetamine. Lancet ii, 524–525.CrossRefGoogle Scholar
Pare, C. M. B. (1965). Treatment of depression. Lancet i, 923–925.Google Scholar
Pare, C. M. B. (1979). Monoamine oxidase inhibitors in resistant depression. International Pharmacopsychiatry 14, 101–109.CrossRefGoogle ScholarPubMed
Poole, S. & Stephenson, J. D. (1977). Core temperature: some shortcomings of rectal temperature measurements. Physiology and Behaviour 18, 203–205.CrossRefGoogle ScholarPubMed
Randell, J. (1965). Combining the antidepressant drugs. British Medical Journal i, 521.CrossRefGoogle Scholar
Ray, I. (1973). Combinations of antidepressant drugs in the treatment of depressive illness. Canadian Psychiatric Association Journal 18, 399–402.CrossRefGoogle ScholarPubMed
Riederer, P., Youdim, M B. H., Rausch, W. D., Birkmayer, W., Jellinger, K. & Seemann, D. (1978). On the mode of action of l-deprenyl in the human central nervous system. Journal of Neural Transmission 43, 217–226.CrossRefGoogle ScholarPubMed
Sargant, W. (1967). Psychotropic drugs. British Medical Journal iii, 861.CrossRefGoogle Scholar
Sargant, W. (1969). Treatment of the phobic state. British Medical Journal iii, 118.CrossRefGoogle Scholar
Sargant, W. (1971). Safety of combined antidepressant drugs. British Medical Journal i, 555–556.CrossRefGoogle Scholar
Schacht, U. & Heptner, W. (1974). Effect of nomifensine (Hoe 984), a new antidepressant on uptake of noracirenaline and serotonin and on release of noradrenaline in rat brain synaptosomes. Biochemical Pharmacology 23, 3413–3422.CrossRefGoogle ScholarPubMed
Schuckit, M., Robins, E. & Feighner, J. (1971). Tricyclic antidepressants and monoamine oxidase inhibitors. Archives of General Psychiatry 24, 509–514.CrossRefGoogle ScholarPubMed
Sethna, E. R. (1974). A study of refractory cases of depressive illnesses and their response to combined antidepressant treatment. British Journal of Psychiatry 124, 265–272.CrossRefGoogle ScholarPubMed
Sinha, J. M., Dhasmana, K. M., Dixit, K. S. & Bhargava, K. P.. (1969). Antagonism of imipramine induced fatal hyperpyrexia in MAO inhibitor treated rabbits. Japanese Journal of Pharmacology 19, 623–625.CrossRefGoogle ScholarPubMed
Sloviter, R. S., Drust, E. G. & Connor, J. D. (1978). Specificity of a rat behavioural model for serotonin receptor activation. Journal of Pharmacology and Experimental Therapeutics 206, 339–347.Google ScholarPubMed
Squires, R. F. (1972). Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: a comparison of eight mammalian species. Advances in Biochemistry and Psychopharmacology 5, 355–370.Google ScholarPubMed
Squires, R. F. & Buus, Lassen J. (1975). The inhibition of A and B forms of MAO in the production of a characteristic behavioural syndrome in rats after L-tryptophan loading. Psychopharmacologia 41, 145–151.CrossRefGoogle Scholar
Tedeschi, D. H., Tedeschi, R. E. & Fellows, E. J. (1959). The effects of tryptamine on the central nervous system, including a pharmacological procedure for the evaluation of iproniazid-like drugs. Journal of Pharmacology and Experimental Therapeutics 126, 223–232.Google ScholarPubMed
White, K. & Simpson, G. (1981). Combined MAOI-tricycic antidepressant treatment: a revaluation. Journal of Clinical Psychopharmacology 1, 264–282.CrossRefGoogle Scholar
White, K., Pistole, T. & Boyd, J. L. (1980). Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study. American Journal of Psychiatry 137. 1422–1425.Google ScholarPubMed
Winston, F. (1971). Combined antidepressant therapy. British Journal of Psychiatry 118, 301–304.CrossRefGoogle ScholarPubMed
Young, J. P. R., Lader, M. H. & Hughes, W. C. (1979). Controlled trial of trimipramine, monoamime oxidase inhibitors and combined treatment in depressed outpatients. British Medical Journal ii, 1315–1317.CrossRefGoogle Scholar